CAMBRIDGE, Mass. — October 9, 2025 — Leads & Copy — Alkeus Pharmaceuticals, Inc. will present results from its clinical study of oral gildeuretinol for moderate Stargardt disease (TEASE-2) at the American Academy of Ophthalmology (AAO) meeting in Orlando, October 18-21, 2025. The presentation, by Dr. Philip J. Ferrone of Vitreoretinal Consultants of New York, is scheduled for Retina Subspecialty Day 2025, October 18, 8:23 a.m. – 8:30 a.m. EDT at the Orange County Convention Center.
Alkeus Pharmaceuticals, based in Cambridge, Mass., focuses on preserving sight for individuals with retinal diseases. Their lead candidate, gildeuretinol acetate (ALK-001), is being evaluated in clinical trials for Stargardt disease. Gildeuretinol aims to reduce vitamin A dimerization without affecting the visual cycle and has received multiple designations from the FDA and EMA.
The TEASE program includes four clinical studies of oral gildeuretinol (ALK-001) in Stargardt disease (TEASE-1, TEASE-2, TEASE-3, and TEASE-4). TEASE-1 and TEASE-2 are completed, while TEASE-3 (NCT02402660) and TEASE-4 (NCT04239625) are ongoing.
Media Relations
media@alkeuspharma.com
Source: Alkeus Pharmaceuticals
